Seagen has described new antibody-drug conjugates (ADCs) comprising antibodies covalently bound to stimulator of interferon genes protein (STING; TMEM173) agonists through a linker and reported to be useful for the treatment of cancer.
WuXi Biologics (Shanghai) and WuXi Biologics Ireland have divulged antibody-drug conjugates (ADCs) comprising anti-TROP2 antibodies covalently linked to cytotoxic drugs via linker reported to be useful for the treatment of cancer.
RP Scherer Technologies has synthesized new antibody-drug conjugates (ADCs) comprising camptothecine or camptothecine derivatives linked to a polypeptide such as an antibody through a linker reported to be useful for the treatment of cancer.
Mersana Therapeutics has entered into an option agreement with GSK for the codevelopment and commercialization of XMT-2056, an Immunosynthen antibody-drug conjugate (ADC) that targets a novel epitope of HER2.
A new method has been devised to produce generic chimeric antigen receptor (CAR) T cells at scale by directing induced pluripotent stem cells (iPSCs) to differentiate into mature T cells in vitro. The generic T cells can then be engineered to express a range of different chimeric antigen receptors.
Pfizer has patented isolated engineered immune cells expressing chimeric antigen receptors (CARs) comprising an epidermal growth factor receptor variant 3 (EGFRvIII) binding domain, a transmembrane domain and an intracellular signaling domain claimed to be potentially useful for the treatment of cancer.
Genmab and BioNTech have expanded their global strategic collaboration to develop and commercialize novel immunotherapies for the treatment of cancer. Under the expansion, Genmab and BioNTech will jointly work to research, develop and commercialize novel monospecific antibody candidates for various cancer indications.
RSS